Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy
: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the overproduction of white blood cells, leading to symptoms such as fatigue, infections, and other complications. CML patients must take measures to prevent infections to mitigate the exacerbation of cancer cell prol...
Gespeichert in:
Veröffentlicht in: | Nutrients 2024-01, Vol.16 (3), p.383 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | 383 |
container_title | Nutrients |
container_volume | 16 |
creator | Pires, Daniela A Brandão-Rangel, Maysa A R Silva-Reis, Anamei Olímpio, Fabiana R S Aimbire, Flavio Oliveira, Carlos R Mateus-Silva, José R Zamarioli, Lucas S Bachi, André L L Bella, Yanesko F Santos, Juliana M B Bincoletto, Claudia Lancha, Jr, Antonio Herbert Vieira, Rodolfo P |
description | : Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the overproduction of white blood cells, leading to symptoms such as fatigue, infections, and other complications. CML patients must take measures to prevent infections to mitigate the exacerbation of cancer cell proliferation and comorbidities.
: This study investigated whether vitamin C can suppress the hyperinflammatory activation of K-562 cells induced by lipopolysaccharide (LPS) and whether purinergic signaling (ATP and P2X7 receptor) and autophagy play a role in it. Two different doses of vitamin C (5 µg/mL and 10 µg/mL) were employed, along with the lysosome inhibitor chloroquine (CQ; 100 µM), administered 2 h prior to LPS stimulation (10 ng/mL) for a duration of 22 h in K-562 cells (3 × 10
cells/mL/well).
: Both doses of vitamin C reduced the release of interleukin-6 (IL-6) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) and tumor necrosis factor (TNF) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) induced by LPS. Furthermore, in LPS + CQ-stimulated cells, vitamin C at a concentration of 10 µg/mL inhibited the expression of LC3-II (
< 0.05). Conversely, both doses of vitamin C led to the release of the anti-inflammatory cytokine interleukin-10 (IL-10) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01), while only the 10 µg/mL dose of vitamin C induced the release of Klotho (10 µg/mL,
< 0.01). In addition, both doses of vitamin C reduced the accumulation of ATP (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) and decreased the expression of the P2X7 receptor at the mRNA level.
: Vitamin C inhibits the hyperinflammatory state induced by LPS in K-562 cells, primarily by inhibiting the ATP accumulation, P2X7 receptor expression, and autophagy signaling. |
doi_str_mv | 10.3390/nu16030383 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2925034620</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A782092114</galeid><sourcerecordid>A782092114</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-be8527e1bf9e416c791fda6eb5eafb08cab376e7fb13de3d575910314fd8ad753</originalsourceid><addsrcrecordid>eNptklFv1SAUxxujccvcix_AkPhiTDqhtNA-3jRzu8k1mkx9bSgcWmYLFehDv4afWO42nRrhAcL5_U_-nHOy7CXBF5Q2-J1dCcMU05o-yU4LzIucsZI-_eN-kp2HcIuPi2PO6PPsJNGUM1afZj--mihmY1GL9nY0vYkBHcziFjdtQUg5Cm8U5HurVgkKXW8LeGP1JOZZROc3dBNFBOQ0akfvrJHowwaTMwodYP0GsxGohWkKKKbwOozo05r04IdE3pjBisnYAQmr0G6NbhnFsL3InmkxBTh_OM-yL-8vP7fX-eHj1b7dHXJZkjrmPdRVwYH0uoGSMMkbopVg0FcgdI9rKfr0R-C6J1QBVRWvGoIpKbWqheIVPcve3OddvPu-QojdbIJMZoUFt4auaIoK05IVOKGv_0Fv3eqT-TuKNpRRwh-pQUzQpSq56IU8Ju12vC5wUxBSJuriP1TaKlVLOgvapPe_BG_vBdK7EDzobvFmFn7rCO6OM9A9zkCCXz04XfsZ1G_0V8fpTwNFrO0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2923936317</pqid></control><display><type>article</type><title>Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Pires, Daniela A ; Brandão-Rangel, Maysa A R ; Silva-Reis, Anamei ; Olímpio, Fabiana R S ; Aimbire, Flavio ; Oliveira, Carlos R ; Mateus-Silva, José R ; Zamarioli, Lucas S ; Bachi, André L L ; Bella, Yanesko F ; Santos, Juliana M B ; Bincoletto, Claudia ; Lancha, Jr, Antonio Herbert ; Vieira, Rodolfo P</creator><creatorcontrib>Pires, Daniela A ; Brandão-Rangel, Maysa A R ; Silva-Reis, Anamei ; Olímpio, Fabiana R S ; Aimbire, Flavio ; Oliveira, Carlos R ; Mateus-Silva, José R ; Zamarioli, Lucas S ; Bachi, André L L ; Bella, Yanesko F ; Santos, Juliana M B ; Bincoletto, Claudia ; Lancha, Jr, Antonio Herbert ; Vieira, Rodolfo P</creatorcontrib><description><![CDATA[: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the overproduction of white blood cells, leading to symptoms such as fatigue, infections, and other complications. CML patients must take measures to prevent infections to mitigate the exacerbation of cancer cell proliferation and comorbidities.
: This study investigated whether vitamin C can suppress the hyperinflammatory activation of K-562 cells induced by lipopolysaccharide (LPS) and whether purinergic signaling (ATP and P2X7 receptor) and autophagy play a role in it. Two different doses of vitamin C (5 µg/mL and 10 µg/mL) were employed, along with the lysosome inhibitor chloroquine (CQ; 100 µM), administered 2 h prior to LPS stimulation (10 ng/mL) for a duration of 22 h in K-562 cells (3 × 10
cells/mL/well).
: Both doses of vitamin C reduced the release of interleukin-6 (IL-6) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) and tumor necrosis factor (TNF) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) induced by LPS. Furthermore, in LPS + CQ-stimulated cells, vitamin C at a concentration of 10 µg/mL inhibited the expression of LC3-II (
< 0.05). Conversely, both doses of vitamin C led to the release of the anti-inflammatory cytokine interleukin-10 (IL-10) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01), while only the 10 µg/mL dose of vitamin C induced the release of Klotho (10 µg/mL,
< 0.01). In addition, both doses of vitamin C reduced the accumulation of ATP (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) and decreased the expression of the P2X7 receptor at the mRNA level.
: Vitamin C inhibits the hyperinflammatory state induced by LPS in K-562 cells, primarily by inhibiting the ATP accumulation, P2X7 receptor expression, and autophagy signaling.]]></description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu16030383</identifier><identifier>PMID: 38337668</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenosine triphosphate ; Adenosine Triphosphate - pharmacology ; Ascorbic Acid - pharmacology ; Autophagy ; B cells ; Bacterial infections ; Biological products industry ; Cancer therapies ; Cell culture ; Cytokines ; Cytotoxicity ; Drug resistance ; Humans ; Infections ; Interleukins ; Kinases ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Lipopolysaccharides - pharmacology ; Receptors, Purinergic P2X7 ; Tumor necrosis factor ; Tumor necrosis factor-TNF ; Vitamin C</subject><ispartof>Nutrients, 2024-01, Vol.16 (3), p.383</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-be8527e1bf9e416c791fda6eb5eafb08cab376e7fb13de3d575910314fd8ad753</citedby><cites>FETCH-LOGICAL-c418t-be8527e1bf9e416c791fda6eb5eafb08cab376e7fb13de3d575910314fd8ad753</cites><orcidid>0000-0001-8266-1416 ; 0000-0003-0527-0723 ; 0000-0001-6379-1143 ; 0000-0003-4710-431X ; 0000-0002-4290-541X ; 0000-0001-8634-2850 ; 0000-0002-9284-8695 ; 0000-0001-6666-3673 ; 0000-0002-6067-1442</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38337668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pires, Daniela A</creatorcontrib><creatorcontrib>Brandão-Rangel, Maysa A R</creatorcontrib><creatorcontrib>Silva-Reis, Anamei</creatorcontrib><creatorcontrib>Olímpio, Fabiana R S</creatorcontrib><creatorcontrib>Aimbire, Flavio</creatorcontrib><creatorcontrib>Oliveira, Carlos R</creatorcontrib><creatorcontrib>Mateus-Silva, José R</creatorcontrib><creatorcontrib>Zamarioli, Lucas S</creatorcontrib><creatorcontrib>Bachi, André L L</creatorcontrib><creatorcontrib>Bella, Yanesko F</creatorcontrib><creatorcontrib>Santos, Juliana M B</creatorcontrib><creatorcontrib>Bincoletto, Claudia</creatorcontrib><creatorcontrib>Lancha, Jr, Antonio Herbert</creatorcontrib><creatorcontrib>Vieira, Rodolfo P</creatorcontrib><title>Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy</title><title>Nutrients</title><addtitle>Nutrients</addtitle><description><![CDATA[: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the overproduction of white blood cells, leading to symptoms such as fatigue, infections, and other complications. CML patients must take measures to prevent infections to mitigate the exacerbation of cancer cell proliferation and comorbidities.
: This study investigated whether vitamin C can suppress the hyperinflammatory activation of K-562 cells induced by lipopolysaccharide (LPS) and whether purinergic signaling (ATP and P2X7 receptor) and autophagy play a role in it. Two different doses of vitamin C (5 µg/mL and 10 µg/mL) were employed, along with the lysosome inhibitor chloroquine (CQ; 100 µM), administered 2 h prior to LPS stimulation (10 ng/mL) for a duration of 22 h in K-562 cells (3 × 10
cells/mL/well).
: Both doses of vitamin C reduced the release of interleukin-6 (IL-6) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) and tumor necrosis factor (TNF) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) induced by LPS. Furthermore, in LPS + CQ-stimulated cells, vitamin C at a concentration of 10 µg/mL inhibited the expression of LC3-II (
< 0.05). Conversely, both doses of vitamin C led to the release of the anti-inflammatory cytokine interleukin-10 (IL-10) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01), while only the 10 µg/mL dose of vitamin C induced the release of Klotho (10 µg/mL,
< 0.01). In addition, both doses of vitamin C reduced the accumulation of ATP (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) and decreased the expression of the P2X7 receptor at the mRNA level.
: Vitamin C inhibits the hyperinflammatory state induced by LPS in K-562 cells, primarily by inhibiting the ATP accumulation, P2X7 receptor expression, and autophagy signaling.]]></description><subject>Adenosine triphosphate</subject><subject>Adenosine Triphosphate - pharmacology</subject><subject>Ascorbic Acid - pharmacology</subject><subject>Autophagy</subject><subject>B cells</subject><subject>Bacterial infections</subject><subject>Biological products industry</subject><subject>Cancer therapies</subject><subject>Cell culture</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Drug resistance</subject><subject>Humans</subject><subject>Infections</subject><subject>Interleukins</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Receptors, Purinergic P2X7</subject><subject>Tumor necrosis factor</subject><subject>Tumor necrosis factor-TNF</subject><subject>Vitamin C</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptklFv1SAUxxujccvcix_AkPhiTDqhtNA-3jRzu8k1mkx9bSgcWmYLFehDv4afWO42nRrhAcL5_U_-nHOy7CXBF5Q2-J1dCcMU05o-yU4LzIucsZI-_eN-kp2HcIuPi2PO6PPsJNGUM1afZj--mihmY1GL9nY0vYkBHcziFjdtQUg5Cm8U5HurVgkKXW8LeGP1JOZZROc3dBNFBOQ0akfvrJHowwaTMwodYP0GsxGohWkKKKbwOozo05r04IdE3pjBisnYAQmr0G6NbhnFsL3InmkxBTh_OM-yL-8vP7fX-eHj1b7dHXJZkjrmPdRVwYH0uoGSMMkbopVg0FcgdI9rKfr0R-C6J1QBVRWvGoIpKbWqheIVPcve3OddvPu-QojdbIJMZoUFt4auaIoK05IVOKGv_0Fv3eqT-TuKNpRRwh-pQUzQpSq56IU8Ju12vC5wUxBSJuriP1TaKlVLOgvapPe_BG_vBdK7EDzobvFmFn7rCO6OM9A9zkCCXz04XfsZ1G_0V8fpTwNFrO0</recordid><startdate>20240129</startdate><enddate>20240129</enddate><creator>Pires, Daniela A</creator><creator>Brandão-Rangel, Maysa A R</creator><creator>Silva-Reis, Anamei</creator><creator>Olímpio, Fabiana R S</creator><creator>Aimbire, Flavio</creator><creator>Oliveira, Carlos R</creator><creator>Mateus-Silva, José R</creator><creator>Zamarioli, Lucas S</creator><creator>Bachi, André L L</creator><creator>Bella, Yanesko F</creator><creator>Santos, Juliana M B</creator><creator>Bincoletto, Claudia</creator><creator>Lancha, Jr, Antonio Herbert</creator><creator>Vieira, Rodolfo P</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8266-1416</orcidid><orcidid>https://orcid.org/0000-0003-0527-0723</orcidid><orcidid>https://orcid.org/0000-0001-6379-1143</orcidid><orcidid>https://orcid.org/0000-0003-4710-431X</orcidid><orcidid>https://orcid.org/0000-0002-4290-541X</orcidid><orcidid>https://orcid.org/0000-0001-8634-2850</orcidid><orcidid>https://orcid.org/0000-0002-9284-8695</orcidid><orcidid>https://orcid.org/0000-0001-6666-3673</orcidid><orcidid>https://orcid.org/0000-0002-6067-1442</orcidid></search><sort><creationdate>20240129</creationdate><title>Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy</title><author>Pires, Daniela A ; Brandão-Rangel, Maysa A R ; Silva-Reis, Anamei ; Olímpio, Fabiana R S ; Aimbire, Flavio ; Oliveira, Carlos R ; Mateus-Silva, José R ; Zamarioli, Lucas S ; Bachi, André L L ; Bella, Yanesko F ; Santos, Juliana M B ; Bincoletto, Claudia ; Lancha, Jr, Antonio Herbert ; Vieira, Rodolfo P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-be8527e1bf9e416c791fda6eb5eafb08cab376e7fb13de3d575910314fd8ad753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adenosine triphosphate</topic><topic>Adenosine Triphosphate - pharmacology</topic><topic>Ascorbic Acid - pharmacology</topic><topic>Autophagy</topic><topic>B cells</topic><topic>Bacterial infections</topic><topic>Biological products industry</topic><topic>Cancer therapies</topic><topic>Cell culture</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Drug resistance</topic><topic>Humans</topic><topic>Infections</topic><topic>Interleukins</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Receptors, Purinergic P2X7</topic><topic>Tumor necrosis factor</topic><topic>Tumor necrosis factor-TNF</topic><topic>Vitamin C</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pires, Daniela A</creatorcontrib><creatorcontrib>Brandão-Rangel, Maysa A R</creatorcontrib><creatorcontrib>Silva-Reis, Anamei</creatorcontrib><creatorcontrib>Olímpio, Fabiana R S</creatorcontrib><creatorcontrib>Aimbire, Flavio</creatorcontrib><creatorcontrib>Oliveira, Carlos R</creatorcontrib><creatorcontrib>Mateus-Silva, José R</creatorcontrib><creatorcontrib>Zamarioli, Lucas S</creatorcontrib><creatorcontrib>Bachi, André L L</creatorcontrib><creatorcontrib>Bella, Yanesko F</creatorcontrib><creatorcontrib>Santos, Juliana M B</creatorcontrib><creatorcontrib>Bincoletto, Claudia</creatorcontrib><creatorcontrib>Lancha, Jr, Antonio Herbert</creatorcontrib><creatorcontrib>Vieira, Rodolfo P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pires, Daniela A</au><au>Brandão-Rangel, Maysa A R</au><au>Silva-Reis, Anamei</au><au>Olímpio, Fabiana R S</au><au>Aimbire, Flavio</au><au>Oliveira, Carlos R</au><au>Mateus-Silva, José R</au><au>Zamarioli, Lucas S</au><au>Bachi, André L L</au><au>Bella, Yanesko F</au><au>Santos, Juliana M B</au><au>Bincoletto, Claudia</au><au>Lancha, Jr, Antonio Herbert</au><au>Vieira, Rodolfo P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy</atitle><jtitle>Nutrients</jtitle><addtitle>Nutrients</addtitle><date>2024-01-29</date><risdate>2024</risdate><volume>16</volume><issue>3</issue><spage>383</spage><pages>383-</pages><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract><![CDATA[: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the overproduction of white blood cells, leading to symptoms such as fatigue, infections, and other complications. CML patients must take measures to prevent infections to mitigate the exacerbation of cancer cell proliferation and comorbidities.
: This study investigated whether vitamin C can suppress the hyperinflammatory activation of K-562 cells induced by lipopolysaccharide (LPS) and whether purinergic signaling (ATP and P2X7 receptor) and autophagy play a role in it. Two different doses of vitamin C (5 µg/mL and 10 µg/mL) were employed, along with the lysosome inhibitor chloroquine (CQ; 100 µM), administered 2 h prior to LPS stimulation (10 ng/mL) for a duration of 22 h in K-562 cells (3 × 10
cells/mL/well).
: Both doses of vitamin C reduced the release of interleukin-6 (IL-6) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) and tumor necrosis factor (TNF) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) induced by LPS. Furthermore, in LPS + CQ-stimulated cells, vitamin C at a concentration of 10 µg/mL inhibited the expression of LC3-II (
< 0.05). Conversely, both doses of vitamin C led to the release of the anti-inflammatory cytokine interleukin-10 (IL-10) (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01), while only the 10 µg/mL dose of vitamin C induced the release of Klotho (10 µg/mL,
< 0.01). In addition, both doses of vitamin C reduced the accumulation of ATP (5 µg/mL,
< 0.01 and 10 µg/mL,
< 0.01) and decreased the expression of the P2X7 receptor at the mRNA level.
: Vitamin C inhibits the hyperinflammatory state induced by LPS in K-562 cells, primarily by inhibiting the ATP accumulation, P2X7 receptor expression, and autophagy signaling.]]></abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38337668</pmid><doi>10.3390/nu16030383</doi><orcidid>https://orcid.org/0000-0001-8266-1416</orcidid><orcidid>https://orcid.org/0000-0003-0527-0723</orcidid><orcidid>https://orcid.org/0000-0001-6379-1143</orcidid><orcidid>https://orcid.org/0000-0003-4710-431X</orcidid><orcidid>https://orcid.org/0000-0002-4290-541X</orcidid><orcidid>https://orcid.org/0000-0001-8634-2850</orcidid><orcidid>https://orcid.org/0000-0002-9284-8695</orcidid><orcidid>https://orcid.org/0000-0001-6666-3673</orcidid><orcidid>https://orcid.org/0000-0002-6067-1442</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6643 |
ispartof | Nutrients, 2024-01, Vol.16 (3), p.383 |
issn | 2072-6643 2072-6643 |
language | eng |
recordid | cdi_proquest_miscellaneous_2925034620 |
source | MEDLINE; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Adenosine triphosphate Adenosine Triphosphate - pharmacology Ascorbic Acid - pharmacology Autophagy B cells Bacterial infections Biological products industry Cancer therapies Cell culture Cytokines Cytotoxicity Drug resistance Humans Infections Interleukins Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Lipopolysaccharides - pharmacology Receptors, Purinergic P2X7 Tumor necrosis factor Tumor necrosis factor-TNF Vitamin C |
title | Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T12%3A38%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20C%20Inhibits%20Lipopolysaccharide-Induced%20Hyperinflammatory%20State%20of%20Chronic%20Myeloid%20Leukemia%20Cells%20through%20Purinergic%20Signaling%20and%20Autophagy&rft.jtitle=Nutrients&rft.au=Pires,%20Daniela%20A&rft.date=2024-01-29&rft.volume=16&rft.issue=3&rft.spage=383&rft.pages=383-&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu16030383&rft_dat=%3Cgale_proqu%3EA782092114%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2923936317&rft_id=info:pmid/38337668&rft_galeid=A782092114&rfr_iscdi=true |